Cloning And Mutagenesis Market Worth $9.44 Billion By 2030

Cloning And Mutagenesis Market Growth & Trends

The global cloning and mutagenesis market size is expected to reach USD 9.44 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 18.97% from 2023 to 2030. Growing focus on protein engineering for drug development and increasing demand for genetically modified products are major factors driving the market. In addition, the rising prevalence of genetic disorders and chronic diseases is increasing the demand for personalized medicine.

Cloning and mutagenesis are the basic methodologies employed in protein engineering during drug development. These techniques help researchers in the modification of protein sequences through insertion, deletion, or substitution of nucleotides to develop therapeutic proteins. In addition, cloning and mutagenesis aid in the development of more efficient and safer drugs, which can be readily available at a lower cost. For instance, currently, there are more than 200 peptide and protein drugs approved by the FDA. Hence, applications of these techniques in protein engineering are likely to fuel market growth over the forecast years.

The COVID-19 pandemic is expected to positively influence market growth. Cloning and mutagenesis techniques are used to clone the SARS-CoV-2 genome. For instance, according to an article published in Nature in May 2020, researchers have constructed a clone of the SARC-CoV-2 genome by using yeast-based method. Modifying or reconstructing genomes is essential for studying methods of infection, replication, and potential drugs and vaccines that might work against the virus. As a result, the usage of these techniques has increased due to COVID-19-related research, which is expected to fuel the market growth during the forecast period.

The growing prevalence of genetic disorders and chronic diseases is increasing the demand for personalized medicine. Cloning and mutagenesis techniques are used in studying a particular disease of an individual to aid diagnosis, develop a treatment plan, and identify the treatment effect. Moreover, increasing funding for personalized medicine is anticipated to boost the applications of cloning and mutagenesis during the study period. For instance, in February 2022, VariantyxS secured funding worth USD 41.5 million to launch novel solutions in precision oncology.

Furthermore, increasing applications of cloning and mutagenesis tools in synthetic biology are accelerating market growth. Synthetic biology is aiding in fine-tuning of already available drugs by using cloning and mutagenesis to improve their therapeutic attributes and produce minimal or no side effects for individuals. Synthetic genes created the way for oncology-focused organizations to develop personalized cancer vaccines to the specific DNA sequence of a patient’s tumor. Several such personalized cancer vaccines are in the clinical phase. There are several gene-based vaccines that are also in development to fight COVID-19, which require cloning and mutagenesis techniques to produce cost-effective and efficient vaccines. Such applications are expected to fuel the market growth during the study period.

On the other hand, high maintenance cost associated with cloning and mutagenesis tools, limited viability of qualified researchers. and the need for advanced training may limit the market growth to a certain extent. However, key players are continuously striving to develop cost-effective instruments and offering several hands-on training programs to overcome the limitations, which is likely to create growth prospects for the market.

 Request a free sample copy or view report summary: Cloning And Mutagenesis Market Report

Cloning And Mutagenesis Market Report Highlights

• By product, the cloning kits segment held the largest share in 2022. This is attributed to the broad range of applications of these kits in biopharmaceuticals, gene therapy, and gene analysis among others

• By technology, the TOPO PCR cloning segment held the largest share in 2022 due to the advantages associated with the technology such as ligation and restriction-free cloning and simple design of primers

• By end-user, the biopharmaceutical and pharmaceutical companies segment held the largest share in 2022 owing to the widespread use of cloning and mutagenesis in biopharmaceuticals for drug discovery and development

• North America dominated the global market in 2022 due to a rise in investment initiatives by the government, increasing incidence of chronic diseases such as cancer, and high demand for biotechnology techniques

• Asia Pacific is expected to grow considerably in the future owing to the increasing R&D investment by governments, rising demand for novel therapeutics, and improving economy

Cloning And Mutagenesis Market Segmentation

Grand View Research has segmented the global cloning and mutagenesis market based on product, technology, end-user, and region:

Cloning And Mutagenesis Product Outlook (Revenue, USD Million, 2018 - 2030)

• Cloning Kits

• Mutagenesis Kits

• Others

Cloning And Mutagenesis Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Topo PCR Cloning

• Blunt End Cloning

• Seamless Cloning

• Site-directed Mutagenesis

• Others

Cloning And Mutagenesis End-user Outlook (Revenue, USD Million, 2018 - 2030)

• Biopharmaceutical & Pharmaceutical Companies

• CROs & CMOs

• Academic & Research Institutes

Cloning And Mutagenesis Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Cloning And Mutagenesis Market

• Agilent Technologies, Inc.

• Thermo Fisher Scientific, Inc.

• New England Biolabs

• Takara Bio Inc.

• Merck KGaA

• Promega Corporation

• Bio-Rad Laboratories, Inc.

• Danaher

• Jena Bioscience GmbH